An overview of Indian COVID-19 vaccine supply and development
Prashant Khadayate, Pharma Analyst at GlobalData, explains what the current state of the COVID-19 pandemic is in India and what vaccine options are currently under development/testing.
List view / Grid view
News
Alter Pharma Group adopts Movilitas.Cloud to ensure safer goods and EU FMD compliance
Movilitas has announced that Alter Pharma Group has adopted its Movilitas.Cloud software to meet requirements throughout the product path and changes in packaging under the EU FMD regulation.
HPAPI facility developed to produce biodegradable contraceptive molecule
A new HPAPI manufacturing unit has been opened in France, with the capability to make a contraceptive with a superior safety profile and high level of biodegradability.
Gilead Sciences to acquire Immunomedics for $21 billion
Gilead is set to acquire Immunomedics for approximately $21 billion, with the transaction anticipated to close in the fourth quarter of 2020.
Baricitinib and remdesivir reduce time to recovery in COVID-19 patient trial
A study of baricitinib in combination with remdesivir has met its primary endpoint in COVID-19 patients, by reducing time to recovery in comparison with only remdesivir.
UK government inks deal for 60 million doses of Valneva COVID-19 vaccine
Valneva has agreed to supply the UK government with 60 million doses of its potential COVID-19 vaccine by the second half of 2021.
Phase III trial to study REGN-COV2, potential COVID-19 antibody treatment
REGN-COV2 will be evaluated alongside standard-of-care in a Phase III study as part of the COVID-19 RECOVERY trial.
Oral COVID-19 vaccine candidate to enter Phase I human trials
Vaxart's application for a Phase I clinical trial to evaluate its oral COVID-19 vaccine candidate has been cleared by the FDA.
NIH launches antithrombotics trials in COVID-19 patients
The adaptive Phase III trials will assess whether various types and doses of blood thinners can prevent COVID-19 patients forming potentially fatal blood clots.
Promising interim results from ALS study testing IPL344
The data suggests disease deterioration was halved in the six Amyotrophic Lateral Sclerosis (ALS) patients treated with IPL344 over eight months.
Phase I trial finds potential COVID-19 antibody treatment safe in healthy volunteers
A first-in-human Phase I clinical trial of potential COVID-19 antibody CT-P59 has shown the treatment is well tolerated in healthy subjects.
British pharma responds to free trade agreement between UK and Japan
The ABPI has said that the new UK-Japan free trade agreement will benefit the pharma industry, providing continuity for life science businesses.
Clinical trial for AstraZeneca Oxford COVID-19 vaccine candidate to resume
After the clinical trial for AZD1222 was halted last week, the studies for AstraZeneca's COVID-19 vaccine candidate will now resume.
Few CMOs equipped to manufacture cell and gene therapies, finds study
A report has said that with only 152 CMOs able to manufacture the 7,000 cell and gene therapies in the pipeline, production bottlenecks may occur.
Impact of COVID-19 on clinical trials continuing, say researchers
An analysis of the impact of COVID-19 on clinical trials has shown this is increasing, with many sites unable to fully resume practice.
